Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prosecuting Part D: Beware of Free Goods, Value Adds

This article was originally published in RPM Report

Executive Summary

Managed care contracts are entering a period of unprecedented scrutiny. With year one of the Medicare Part D program drawing to a close, prosecutors are preparing to take the gloves off. What will they be looking for?

You may also be interested in...



Off-Label Sales in Jeopardy: Rx Industry Fights for Clarity

Off-label use of prescription drugs is worth billions of dollars to manufacturers, but no one likes to talk about it. Defensiveness is understandable, with scores of companies under investigations for allegedly promoting those uses illegally. The truth is that no one is very happy about the current state of off-label medication use, but calls for change are contradictory and tough to resolve.

Health Care Trends (03/2007): The Case for Pay-for-Performance

The pay-for-performance (P4P) model, which allows hospitals and physicians to be compensated with higher payer reimbursement for providing documented quality care, is becoming a standard practice with a growing number of private insurers, and the federal government wants to use a P4P system for Medicare.

Making Part D Stick: Lessons From the First Year of Medicare Rx

Medicare beneficiaries stuck with their Part D plans heading into 2007. That gives insurers more leverage in price negotiations with big pharma. It also means Part D may be more likely to stick around despite critics in the Democratic Congress.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS080239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel